<?xml version="1.0" encoding="UTF-8"?>
<p id="p0080">The second item which needs consideration is the success rate of vaccine development from clinical trial authorization to License. Typically, this rate was &lt;10% during the period 2000-2010. A 2016 study showed that around 20% of vaccine clinical trials make up from phase I to license.
 <xref rid="bib57" ref-type="bibr">
  <sup>57</sup>
 </xref> Of the 37 vaccines developed for the Ebola virus, only one was licensed based on efficacy and safety in the phase II trial. In the COVID-19 vaccine landscape, investigators have introduced a few new generation vaccines based on nucleic acid technology. Such vaccine technology is not in clinical practice against any infectious disease, and experts believe the success rate of such a vaccine to get licensed is not more than 5%.
 <xref rid="bib58" ref-type="bibr">
  <sup>58</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib59" ref-type="bibr">
  <sup>59</sup>
 </xref>
</p>
